U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07599137) titled 'Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy' on May 07.
Brief Summary: Abemaciclib combined with endocrine therapy has become one of the important adjuvant treatment regimens for patients with HR+/HER2- high-risk early breast cancer. However, adverse events such as diarrhea, fatigue, neutropenia and elevated liver enzymes are concentrated in the early stage of adjuvant therapy, which often lead to dose reduction, temporary drug interruption or even permanent discontinuation. This further affects treatment adherence, relative dose intensity (RDI) and treatment completion rate.
Findings from the TRADE...